-$0.41 Earnings Per Share Expected for Scholar Rock Holding Corp (NASDAQ:SRRK) This Quarter
Equities research analysts forecast that Scholar Rock Holding Corp (NASDAQ:SRRK) will post ($0.41) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Scholar Rock’s earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.42). Scholar Rock posted earnings per share of ($1.39) in the same quarter last year, which would suggest a positive year over year growth rate of 70.5%. The company is expected to announce its next quarterly earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Scholar Rock will report full-year earnings of ($1.83) per share for the current year, with EPS estimates ranging from ($1.94) to ($1.64). For the next year, analysts anticipate that the firm will report earnings of ($2.27) per share, with EPS estimates ranging from ($2.94) to ($1.42). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Scholar Rock.
Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Tuesday, May 14th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.08. The business had revenue of $3.11 million during the quarter, compared to analyst estimates of $5.05 million.
Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in shares of Scholar Rock in the third quarter worth $351,000. Vanguard Group Inc lifted its stake in shares of Scholar Rock by 479.1% in the third quarter. Vanguard Group Inc now owns 231,656 shares of the company’s stock worth $5,966,000 after buying an additional 191,656 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Scholar Rock in the fourth quarter worth $147,000. BB Biotech AG lifted its stake in shares of Scholar Rock by 573.8% in the fourth quarter. BB Biotech AG now owns 1,279,978 shares of the company’s stock worth $29,401,000 after buying an additional 1,090,021 shares during the last quarter. Finally, Teachers Advisors LLC acquired a new stake in shares of Scholar Rock in the third quarter worth $206,000. Institutional investors and hedge funds own 52.76% of the company’s stock.
Shares of Scholar Rock stock traded up $0.17 on Wednesday, reaching $17.49. The stock had a trading volume of 32,486 shares, compared to its average volume of 92,417. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.05. Scholar Rock has a fifty-two week low of $13.09 and a fifty-two week high of $30.00. The stock has a market capitalization of $454.30 million and a price-to-earnings ratio of -5.55.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Featured Story: The mechanics of the bid-ask spread in trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.